⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Supplementary Figure S4 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial

Melissa L. Abel Nobuyuki Takahashi Cody J. Peer Christophe E. Redon Samantha Nichols Rasa Vilimas Min-Jung Lee Sunmin Lee Meenakshi Shelat Robbie Kattapuram Linda Sciuto Danielle Pinkiert Chante Graham Donna Butcher Baktiar Karim Ajit Kumar Sharma Justin Malin Rajesh Kumar Christopher W. Schultz Shubhank Goyal Jaydira Del Rivero Manan Krishnamurthy Deep Upadhyay Brett Schroeder Tristan M. Sissung Manoj Tyagi Jung Kim Yves Pommier Mirit I. Aladjem Mark Raffeld William D. Figg Jane B. Trepel Liqiang Xi Parth Desai Anish Thomas

View at Publisher

Ask AI

Bookmark

Share

Abstract

Comparison of treatment-related adverse events with the combination of berzosertib and topotecan

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Abel et al. (2024) studied this question.

synapsesocial.com/papers/68e586c1b6db643587523a85 https://doi.org/10.1158/1078-0432.27031510

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S4 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial2024
2Supplementary Data S1 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial2024
3Supplementary Data S1 from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial2024
4Data from Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial2024
5Supplementary Figure S4 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer2024

Supplementary Figure S4 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer2024
Supplementary Figure S1 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer2024
Supplementary Figure S1 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer2024